After the US Food and Drug Administration (USFDA) sent a warning letter to Lupin over manufacturing errors at Maharashtra's Tarapur plant, the drugmaker said, "We are committed to addressing the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest." It added that this wouldn't disrupt the plant's supplies or existing revenue.